Market is huge: Arthritis is the most common cause of disability in the United States, limiting the activities of nearly 21 million adults.
About LODOTRA LODOTRA/RAYOS(in US) is a proprietary programmed-release formulation of low-dose prednisone and has received regulatory approval for the treatment of moderate to severe active rheumatoid arthritis (RA) when accompanied by morning stiffness in Europe where it is promoted by Mundipharma. LODOTRA utilizes SkyePharma's proprietary Geoclock™ technology.
PDUFA--July 27 Insiders and institutions-- Net institutional purchases in the current quarter at 2.3M shares, which represents about 9.07% of the company's float of 25.35M shares. Over the last six months, insiders were net buyers of 1,511,150 shares, which represents about 5.96% of the company's 25.35M share float. http://tiny.cc/5aj8ew
From various sources: ***lodotra already approved in EU ***private placement was done at 3.62 + warrants for .25 shrs, exercise 4.308 ***generic threat put off for 30 months ***company is doubling US sales force to 160, boots on the ground ***they announced expansion into latin america ***outperform or accumulate ratings(2) price targets $10 and $16 ***insiders buying at higher prices ***per company cash to last through Q1 2013
For me this is a mid-term swing
I think we will see significantly higher price before 7/27.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.